Načítá se...
Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy
BACKGROUND: In dystrophin-deficient muscles of Duchenne Muscular Dystrophy (DMD) patients and the mdx mouse model, nitric oxide (NO) signalling is impaired. Previous studies have shown that NO-donating drugs are beneficial in dystrophic mouse models. Recently, a long-term treatment (9 months) of mdx...
Uloženo v:
| Vydáno v: | Orphanet J Rare Dis |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4546261/ https://ncbi.nlm.nih.gov/pubmed/26296873 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-015-0311-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|